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Abstract 
Background and purpose:  Recent findings suggest that a gait assessment at a discrete moment in a clinic or labo‑
ratory setting may not reflect functional, everyday mobility. As a step towards better understanding gait during daily 
life in neurological populations, we compared gait measures that best discriminated people with multiple sclerosis 
(MS) and people with Parkinson’s Disease (PD) from their respective, age‑matched, healthy control subjects (MS‑Ctl, 
PD‑Ctl) in laboratory tests versus a week of daily life monitoring.
Methods:  We recruited 15 people with MS (age mean ± SD: 49 ± 10 years), 16 MS‑Ctl (45 ± 11 years), 16 people with 
idiopathic PD (71 ± 5 years), and 15 PD‑Ctl (69 ± 7 years). Subjects wore 3 inertial sensors (one each foot and lower 
back) in the laboratory followed by 7 days during daily life. Mann–Whitney U test and area under the curve (AUC) 
compared differences between PD and PD‑Ctl, and between MS and MS‑Ctl in the laboratory and in daily life.
Results:  Participants wore sensors for 60–68 h in daily life. Measures that best discriminated gait characteristics in 
people with MS and PD from their respective control groups were different between the laboratory gait test and 
a week of daily life. Specifically, the toe‑off angle best discriminated MS versus MS‑Ctl in the laboratory (AUC [95% 
CI] = 0.80 [0.63–0.96]) whereas gait speed in daily life (AUC = 0.84 [0.69–1.00]). In contrast, the lumbar coronal range 
of motion best discriminated PD versus PD‑Ctl in the laboratory (AUC = 0.78 [0.59–0.96]) whereas foot‑strike angle in 
daily life (AUC = 0.84 [0.70–0.98]). AUCs were larger in daily life compared to the laboratory.
Conclusions: Larger AUC for daily life gait measures compared to the laboratory gait measures suggest that daily 
life monitoring may be more sensitive to impairments from neurological disease, but each neurological disease may 
require different gait outcome measures.
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Background
Gait impairments are very common in patients with neu-
rological disorders, leading to an elevated risk of falls and 
reduced quality of life [1–3]. Quantitative gait assessment 
can often determine the problem(s) underlying the gait 
impairment and then can be useful to test an efficacy of 
a new intervention. However, until recently, quantitative 
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gait assessments were limited to specialized laboratories, 
under well-controlled conditions. Although laboratory 
gait assessments provide information about gait under 
controlled conditions, they may not reflect actual, func-
tional gait performance during daily activities [4–6]. It 
is likely that increased attention to the walking task and 
awareness of being observed (Hawthorne effect) mini-
mizes gait impairments in the laboratory while divided 
attention, cluttered environments, varied sensory condi-
tions, and fatigue may result in worse gait impairments 
during daily life. Thus, gait assessment in the labora-
tory reflects a person’s capacity (what a person can do), 
whereas gait during daily life reflects a person’s functional 
performance (what a person is actually doing) [5, 6]. This 
understanding is important while conducting research 
as we might see only optimal performance during clini-
cal or laboratory visits and daily performance may be 
worse than what is observed in these prescribed tasks. 
As a result, clinicians might underestimate potential gait 
impairments related to daily life functional abilities.
Further, specific types of mobility impairments differ 
depending upon the neurological disorder. For exam-
ple, gait in people with MS is characterized by reduced 
endurance, spasticity, and ataxia, whereas gait in people 
with PD is characterized by bradykinesia, shuffling, rigid-
ity, freezing, and difficulties turning [7–10]. Slowed gait 
speed is very common with any neurological disorder or 
age [11]. However, slow gait is a general, universal char-
acteristic of impaired mobility and hence, may not be the 
most specific nor discriminative mobility impairment in 
each neurological disorder.
Recently, the use of wearable technology has made it 
feasible to quantify gait in the laboratory and during daily 
life [12–30]. Several studies have compared the quality of 
mobility in the laboratory with daily life walking bouts [5, 
14, 31–33]; however, these studies did not compare simi-
lar gait bout lengths in the two environments (laboratory 
versus daily life) except for the one recent study in chil-
dren with cerebral palsy [32]. Specifically, Del Din et al. 
[14] compared 10-m walking bout in the laboratory to all 
walking bouts during daily life in people with PD, Storm 
et al. [31] compared 15-m and 1-min walking bout in the 
laboratory to all bouts with < 50 steps, between 51 to 100 
steps and > 100 steps in people with MS. Hillel et al. [5] 
compared 1-min laboratory walking bout to daily life 
walking bout of 30-s only in people with PD. Shema-Shi-
ratzky et al. [33] compared the first 30-s of 1-min labora-
tory walking bout to daily life walking bout of 30-s and 
more in people with MS. Matching gait bout length is 
important because many gait measures change with the 
duration of a walking bout [14], [34]. In addition, people 
very seldom, if ever, walk for more than 1-min continu-
ously or in a straight line for over 10-m during daily life 
like they do in laboratory tests [4, 5, 14, 31]. Thus, com-
parisons of strides taken from long, steady-state gait in 
the laboratory with all the strides measured in daily life 
are confounded by differences in gait bout length. Hence, 
in this study, we focused on short walk test in the labora-
tory and compared the gait characteristics in the labora-
tory to similar short walking bouts during daily life.
In this study, we aimed to identify a set of gait measures 
that best discriminated gait characteristics from a single 
short walk gait test in the laboratory between people with 
MS and their age-matched healthy control subjects (MS-
Ctl), and between people with PD and their older, age-
matched healthy control subjects (PD-Ctl) and compared 
those gait quality measures to a week of daily life gait 
quality measures from a similar short bout length using 
wearable sensors. We investigated whether gait meas-
ures that best discriminate gait impairments in MS and 
PD versus their respective control cohorts during labora-
tory assessments remain the same during a week of daily 
life assessment. Further, we investigated the group dif-
ferences between laboratory and daily life gait measures 
for MS, MS-Ctl, PD, and PD-Ctl. We hypothesized that: 
(1) different gait measures would best discriminate PD 
vs. PD-Ctl and MS vs. MS-Ctl in the laboratory and daily 
life, and (2) daily life gait would be more discriminative 
than laboratory measures for both neurological groups. 
Recent studies have shown that the laboratory gait meas-
ures do not reliably reflect daily life gait measures in 
people with PD and MS [5, 14, 33]. Hence, we expected 
different gait measures would discriminate in the labora-
tory and daily life for both neurological groups. We also 
expected that daily life would provide a more complete 
picture of functional performance in a complex environ-
ment, such that group differences would be more evident 
in daily life compared to laboratory gait measures. Fur-
ther, we explored which specific gait measures were the 
most discriminative for the PD and the MS groups, both 
in the laboratory and daily life.
Methods
Participants
We recruited people with MS, age-matched MS-Ctl, 
people with PD, and age-matched PD-Ctl for this study 
which is the part of a larger, longer study to identify gait 
measures that predict prospective falls in MS and PD. 
Our cohort with MS was younger than the cohort with 
PD, so we recruited younger and older control groups 
for comparison. Inclusion and exclusion criteria were the 
same as described in Shah et al. [35]. Specifically, inclu-
sion criteria for PD were a diagnosis of idiopathic Par-
kinson’s disease from movement disorders neurologist 
with the United Kingdom Parkinson’s disease Society 
Brain Bank criteria, Hoehn & Yahr scores of II-IV, and 
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complaints about gait. Inclusion criteria for MS were 
a diagnosis of relapsing–remitting MS confirmed by a 
neurologist specialist, a mild-to-moderate MS-associ-
ated disability (patient-reported EDSS score ≤ 6.0), and 
complaints about gait. Exclusion criteria for all subjects 
included the inability to follow protocol instructions, 
other factors affecting gait such as musculoskeletal dis-
orders, uncorrected vision or vestibular problems, or 
inability to stand or walk in the home without an assis-
tive device. The experimental protocol was approved by 
the Institutional Review Board of the Oregon Health & 
Science University (eIRB #15578). The experimental 
protocol was carried out in accordance with the institu-
tion’s ethical committee, and all the participants provided 
informed written consent.
Laboratory data collection
In the laboratory, subjects were asked to wear 3 inertial 
sensors (Opals by APDM Wearable Technologies, Port-
land, OR, USA; Fig. 1a); one sensor on top of each foot, 
and one over the lower lumbar on an elastic belt. Each 
Opal sensor includes a tri-axial accelerometer, gyroscope, 
and magnetometer with a sampling rate of 128 Hz. The 
Opal is lightweight (22 g), has a battery life of 16 h, and 
includes 8 GB of storage, that can record over 30 days of 
data. All the subjects performed the Instrumented Stand 
and Walk test (ISAW) [36]. The ISAW consists of stand-
ing quietly for 30  s, followed by a verbal instruction to 
initiate gait, walk 7  m, turn 180 degrees after crossing 
a line on the ground, and return to the initial starting 
position [36]. The ISAW test was designed to measure 
postural sway, step initiation, gait, and turning, all in one 
short test. Individuals with MS completed estimates of 
the severity of MS with Patient-Reported Expanded Dis-
ability Status Scale (PREDSS) [37, 38], walking ability 
with Multiple Sclerosis Walking Scale (MSWS-12) [39], 
and fatigue with Modified Fatigue Index Scale (MFIS) 
[40]). PD severity was assessed by a certified researcher 
using the Movement Disorders Society-Unified Parkin-
son’s Disease Rating Scale (MDS-UPDRS), Part III [41]). 
All subjects were tested in the laboratory 1 h after taking 
their regular medication intake (ON-medication state), 
because most of the time, subjects attempt to be in the 
ON-medication state in daily life.
Daily life gait data collection
Subjects were asked to wear instrumented socks (pro-
totype developed by APDM Wearable Technologies, 
Portland, OR, USA; Fig. 1b) on each foot, and one Opal 
sensor over the lower lumbar area with an elastic belt. 
They wore the sensors for at least 8 h/day for a week of 
daily life. To reduce the burden on  participants of try-
ing to securely attach the Opal  monitors  to the outside 
of  their shoes, APDM Wearable Technologies  designed 
an instrumented sock that wraps around the partici-
pant’s foot and ankle with the inertial sensor inserted into 
a small, lightweight pocket  in the foot area. The  inertial 
sensor within the  sock  is located on the dorsum of the 
foot  like the  Opal sensors worn in the laboratory,  The 
main unit containing the battery is  located in a second 
pocket  just above the lateral malleolus. To maximize fit, 
the socks come in different sizes, and the Velcro attach-
ment around the foot and ankle is adjustable to ensure 
that a snug fit and that the sensor does not move on the 
foot while being worn. Thus the inertial system fits into 
the instrumented sock for ease of application and safe, 
unobtrusive use. The instrumented socks and Opals have 
the same inertial sensors with the same sensor specifica-
tions but different  form factor. The instrumented socks 
are synchronized with the Opal worn on the lumbar area. 
This allowed subjects to comfortably wear the instru-
mented socks in their shoes or slippers, and without a 
visually-distracting external strap attachment. It also 
eliminated the task of securing the monitors on the shoes, 
especially important for people (such as people with PD), 
who have difficulty with fine motor movements, such as 
tying shoelaces. The subjects removed the socks and the 
belt at night to recharge the batteries. Data were stored in 
the 8 GB internal memory of the Opals and socks. Sub-
jects returned instrumented socks either by mail using a 
pre-paid box after completion of a week of data collec-
tion or to a research assistant who met subjects at their 
homes. Data were uploaded to a secure cloud-based 
Fig. 1 Sensor placement on feet. a Opal inertial sensor on foot for 
laboratory testing. b Instrumented sock prototype for daily life data 
collection. Note inertial sensor located over lateral metatarsals and 
battery located just above lateral malleolus
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database upon return of the devices and downloaded to a 
local computer for further processing using the same gait 
algorithms for laboratory and daily life gait (after identifi-
cation of appropriate length gait bouts).
Measures of gait
The algorithms used for extracting spatial and temporal 
measures of gait and turning are identical for laboratory 
and daily life gait and have been detailed previously [35, 
42]. In addition, the daily life algorithm first searches for 
possible bouts of walking using a time-domain approach 
to inertial sensor data from the feet and for turns based 
on yaw rotational orientation of the pelvis. Second, indi-
vidual steps are combined into potential bouts of walk-
ing, as long as the duration from one step to the next step 
is no longer than 2.5  s. Finally, each possible bout that 
contains at least 3 steps and is at least 3 s in duration is 
processed with the commercial gait analysis algorithms 
included in Mobility Laboratory (APDM Wearable Tech-
nologies, Portland, Oregon) [36, 43, 44]. Our gait analy-
sis algorithm uses the Unscented Kalman Filter to fuse 
information from the accelerometers, gyroscopes, and 
magnetometers to precisely estimate the orientation and 
position trajectory of each foot between quiet stance 
periods [45, 46]. This approach reduces the problem of 
tracking over a long period of time.
To compare between in-laboratory and daily life gait 
measures, we used only gait bouts that had a similar 
number of strides during the ISAW test in the labora-
tory and during free-living daily activities (4–15 strides 
in about). Specifically, we calculated number valid of 
strides for the ISAW test in the laboratory for all partici-
pants and found that it ranged between 4 to 15 strides, so 
for the bout analysis in daily life we used the same range 
(4–15 strides) corresponding to the stride range observed 
in the laboratory ISAW test. In total, we chose 13 gait 
measures (see Fig. 3 and Additional file 1: Table S1) that 
are commonly used to characterize gait in the laboratory 
and grouped them into three aspects of gait for simplic-
ity: 3 upper-body, 5 spatial, and 5 temporal measures of 
gait [47]. We avoided comparing the coefficient of vari-
ation measures as it is affected by the environment and 
by bout length [48], and also the number of strides in a 
bout for our analysis was less than the minimum number 
of strides required to accurately calculate a coefficient of 
variation (20 strides) [49, 50].
Statistical analysis
The normality of data was determined with Shapiro–
Wilk tests and parametric analysis was used, unless oth-
erwise stated. Independent t-tests or Mann–Whitney U 
tests (if not normally distributed) were used to compare 
between-group differences in subject characteristics, 
adherence, and total weekly walking bouts. As not all gait 
quality measures in the laboratory and during daily life 
were normally distributed, to be consistent, non-para-
metric test (Mann–Whitney U test) was used to compare 
differences between groups for all gait measures (i.e., MS 
vs MS-Ctl and PD vs PD-Ctl). In addition, we computed 
Receiving Operating Characteristics (ROC) and calcu-
lated the Area Under Curve (AUC) [51] to discriminate 
gait measures in people with MS from MS-Ctl and peo-
ple with PD from PD-Ctl, and ordered measures from the 
highest to lowest AUC value. Paired Wilcoxon tests were 
used to compare the laboratory and daily life gait meas-
ures for MS, MS-Ctl, PD, and PD-Ctl. All statistical anal-
ysis was performed using R Version 1.1.456 software. The 
statistical significance was set to p < 0.05, and we used 
threshold of p ≤ 0.004 based on the Bonferroni’s correc-




Fifteen people with MS, 16 age-match MS-Ctl, 16 peo-
ple with PD (Hoehn and Yahr stage with II (n = 26), III 
(n = 2), and IV (n = 1)), and 15 age-matched PD-Ctl par-
ticipated in the study. Table  1 shows the demographics 
and activity characteristics of subjects who participated 
in this study. Age, height, and weight were similar 
between the MS and MS-Ctl and between the PD and 
PD-Ctl groups. Adherence to the weekly recordings 
for each subject group was similar with 60.19 ± 11.02 
(mean ± SD) hours in MS, 64.15 ± 9.59  h in MS-Ctl, 
67.66 ± 12.53  h in PD, and 64.67 ± 10.13  h in PD-Ctl 
of daily life data. The histogram in Fig.  2 illustrates the 
number of strides in each bout during daily life, and it is 
evident that the stride range (4–15 strides) in a bout con-
sidered for the analysis in this study captures the major 
portion of participants’ daily activity.
Laboratory versus daily life gait measures discriminating 
gait in MS from MS‑Ctl
Measures discriminating gait characteristics in people 
with MS from MS-Ctl in laboratory versus daily life were 
different (see Table  2 and Fig.  3a). Specifically, the toe-
off angle was the most discriminative in the laboratory 
(p = 0.004; AUC [95% CI] = 0.796 [0.628–0.964]) whereas 
gait speed was in daily life (p = 0.001; AUC = 0.842 
[0.686–0.998]). Stride length was the second best dis-
criminative measure in the laboratory (p = 0.027; 
AUC = 0.735 [0.556–0.915]) whereas the duration of 
swing phase as percent of gait cycle was in daily life 
(p = 0.002; AUC = 0.812 [0.648–0.977). Furthermore, 
more gait measures discriminated MS from MS-Ctl in 
Page 5 of 12Shah et al. J NeuroEngineering Rehabil          (2020) 17:159  
Table 1 Demographics, adherence, and weekly activity of each group
MS multiple sclerosis, MS-Ctl age-matched control subjects corresponding to MS, PD Parkinson’s disease, PD-Ctl age-matched control subjects corresponding to PD, 
PREDSS Patient-Reported Expanded Disability Status Scale, MSWS Multiple Sclerosis Walking Scale, MFIS Modified Fatigue Index Scale, UPDRS Unified Parkinson’s 










Mean SD Mean SD Mean SD Mean SD
Age (yrs) 48.73 10.13 44.63 10.73 0.29 70.5 5.11 68.6 6.50 0.44
Height (m) 1.70 0.09 1.67 0.08 0.98 1.73 0.09 1.73 0.12 0.84
Weight (kg) 72.36 21.03 65.43 11.55 0.58 75.38 14.02 76.99 17.90 0.70
PREDSS (#) 4.27 0.70
MSWS (#) 29.00 8.91
MFIS (#) 38.80 17.01
UPDRS III ON (#) 30.44 10.76
H & Y Stage (#) 2.25 0.56
Total hours (#) 60.19 11.41 64.15 9.91 0.32 67.66 12.95 64.67 10.49 0.55
Total Bouts (#) 467.67 183.41 656.69 225.71 0.02 585.50 300.03 619.73 215.04 0.71
Bouts used for analysis (#) 228.33 113.40 282.88 118.96 0.20 292.25 145.99 272.33 95.73 0.91
Fig. 2 Histogram of the grouped total of bout during daily life for each group. The dashed line indicates the range of the number of strides in the 
bout used for the analysis
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daily life (n = 3) compared to the laboratory (n = 1), after 
the Bonferroni’s correction (13 multiple tests).
Laboratory versus daily life gait measures discriminating 
gait in PD from PD‑Ctl
Most of the measures discriminating gait characteris-
tics in people with PD from PD-Ctl in laboratory versus 
daily life were different (see Table 3 and Fig. 3b). Specifi-
cally, the lumbar coronal range of motion was the most 
discriminative in the laboratory (p = 0.010; AUC = 0.775 
[0.589–0.961]) whereas the foot-strike angle was in daily 
life (p = 0.001; AUC = 0.838 [0.697–0.978]). The foot-
strike angle was the second best discriminative in the lab-
oratory (p = 0.011; AUC = 0.767 [0.578–0.955]) whereas 
gait speed was in daily life (p = 0.003; AUC = 0.804 
[0.632–0.976]). Furthermore, more daily life (n = 2) than 
laboratory (n = 0) measures discriminated gait in the 
PD group from the PD-Ctl group, after the Bonferroni’s 
correction.
Laboratory versus daily life gait measures for each group
Generally, the gait characteristics in daily life compared 
to the laboratory reflected a slowing down behavior in all 
groups, and subjects performed better in the laboratory 
compared to daily life (see Fig. 4). Specifically, looking at 
the gait measures that were significant after the Bonfer-
roni’s correction in PD and MS groups, gait speed (except 
MS-Ctl), swing duration (% of the gait cycle), and the toe-
off angle were significantly lower in daily life compared 
to the laboratory in all groups. Further, double support 
time was significantly longer in daily life compared to the 
laboratory in all groups. In contrast, the foot strike angle 
was not statistically significant between laboratory and 
daily life in all groups except for MS-Ctl.
Discussion
In this study we used similar length, short walking bouts 
in the laboratory and daily life to investigate whether the 
best discriminative gait measures for PD and MS versus 
their respective age-matched controls remain the same 
in a laboratory walking test and daily life walking. Our 
findings demonstrated that the best measures discrimi-
nating gait characteristics in a laboratory versus daily life 
both in the MS and PD groups were different. Specifi-
cally, for people with MS, the toe-off angle was the most 
discriminative in the laboratory, whereas gait speed best 
discriminated in daily life. For people with PD, the lum-
bar coronal range of motion was the most discriminative 
in the laboratory (although not significant after the Bon-
ferroni’s correction), whereas foot- strike angle best dis-
criminated in daily life.
Although the gait measures discriminating MS and 
PD gait characteristics from their age-matched control 
groups were different, we observed an increased in the 
ability to discriminate neurological from control groups 
(i.e., AUC) for daily life gait measures compared to lab-
oratory gait measures. All groups showed improved 
walking characteristics in the laboratory test compared 
to daily life, even though we controlled for bout length, 
unlike previous studies [5, 14]. For example, the gait 
speed was significantly higher in laboratory compared 
to daily life for all groups suggesting that the laboratory 
Table 2 Comparison of gait measures between MS and control groups in the laboratory and during daily life
Italics indicates p < 0.05, and † indicates if the p-value ≤ 0.004 level of significance after Bonferroni correction (that is, 0.05/13 = 0.004)













Mean SD Mean SD Mean SD Mean SD
Cadence (steps/min) 114.11 9.69 112.59 10.9 0.770 106.92 8.36 99.57 7.68 0.005
Double Support (%) 20.3 2.65 22.06 4 0.129 22.67 3.55 26.85 3.61 0.002†
Elevation at Mid Swing (cm) 0.81 0.32 1.07 0.47 0.155 2.98 0.69 2.71 0.53 0.299
Gait Speed (m/s) 1.11 0.15 1 0.16 0.097 1 0.17 0.8 0.13 0.001†
Foot Strike Angle (degrees) 17.97 3.34 15.65 4.68 0.188 19.38 2.64 16.25 4.16 0.037
Toe Off Angle (degrees) 36.31 3.44 31.85 3.97 0.004† 27.97 3.83 23.96 4.01 0.017
Stride Duration (s) 1.06 0.09 1.08 0.11 0.767 1.17 0.1 1.25 0.1 0.017
Stride Length (m) 1.16 0.11 1.07 0.13 0.027 1.1 0.16 0.95 0.15 0.019
Swing (%) 39.84 1.34 38.91 2.1 0.123 38.81 1.85 36.58 1.85 0.002†
Toe Out Angle (degrees) 9.57 4.45 11.13 6.16 0.358 17.93 8.47 18.89 11.51 0.599
Lumbar—Coronal ROM (degrees) 8.47 1.45 7.22 1.91 0.040 7.45 1.72 6.31  1.72 0.151
Lumbar—Sagittal ROM (degrees) 6.18 2.26 6.15 1.86 0.752 6.87 1.15 6.87 1.15 0.740
Lumbar—Transverse ROM (deg) 8.75 2.85 9.79 2.57 0.286 16.62 2.87 16.62 1.72 0.338
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Fig. 3 AUC (in descending order with 95% CI) for each mobility measure discriminating a people with MS from MS‑Ctl, and b people with PD from 
PD‑Ctl. The color‑coding scheme is based on three aspects of gait
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walking while observed may be due to the Hawthorne 
effect or to the lack of distractions and complexity of the 
environment [5]. Interestingly, the difference between the 
laboratory and daily life gait measures were the largest 
(for example, gait speed, and percentage of double sup-
port during the gait cycle) for people with PD. The large 
deterioration in gait characteristics during daily life sug-
gests either that people with PD have a stronger white 
coat effect than the other groups, or that their gait is 
more impaired by challenges in daily life, such as distrac-
tions to attention, clutter, etc.
Gait in people with MS
Long double-support time, slow gait speed, and short 
swing time (all affected by balance impairment and 
fatigue) [7, 9, 52] were significantly different daily life gait 
measures in MS from MS-Ctl. Indeed, gait speed dou-
ble-support time and swing time as a percent of the gait 
cycle all discriminated gait in people with MS from gait 
in healthy control people over a week of daily life with a 
similar, excellent area under the curve [35]. In contrast, in 
the laboratory, the toe-off angle was the only laboratory 
gait measure that discriminated our mild-moderate MS 
from MS-Ctl group during comfortable-pace gait after 
Bonferroni’s correction for 13 gait characteristics. This 
result is consistent with our previous report of a small 
toe-off angle in a separate group of people with MS dur-
ing a 2-min walk in the laboratory [53]. The toe-off angle 
is a surrogate for the push-off phase of gait produced by 
the power in the gastrocnemius-soleus complex, respon-
sible for stride length and gait speed.
Gait in people with PD
Slow gait speed (representing hypokinetic gait) and 
small foot strike angle (representing shuffling of gait) 
were significantly different daily life gait measures in 
the PD group compared to the PD-Ctl group. Previous 
studies of gait in daily life agree that foot strike angle 
[35], and gait speed [14] discriminated gait in PD from 
healthy control groups. Surprisingly, none of the labo-
ratory gait measures discriminated gait characteris-
tics in mild-moderate PD (ON state), from the PD-Ctl 
group, after Bonferroni’s correction, suggesting that 
monitoring gait during daily life is more sensitive to 
impairments from PD than gait test in the laboratory. 
The participants with PD showed much larger changes 
in their gait parameters between the laboratory and 
daily life than the controls or people with MS. This dif-
ference in performance in a laboratory test and daily 
life in people with PD may be due to their reliance on 
less automatic, more attention demanding gait mecha-
nisms that would make gait in daily life more challeng-
ing [54]. The difference could also be due to people with 
PD being more prone to placebo effects and white coat 
effects than the other groups, so they perform better 
when their performance is observed. Alternatively, it 
might be that we picked up the ON and OFF fluctua-
tions during daily life that influenced the averaged gait 
measures over a week. Nevertheless, assessing mobility 
during daily life resulted in more sensitive and specific 
differences in gait characteristics than laboratory gait 
between the PD and control groups.
Table 3 Comparison of gait measures between PD and control groups in the laboratory and during daily life
Italics indicates p < 0.05, and † indicates if the p-value ≤ 0.004 level of significance after Bonferroni correction (that is, 0.05/13 = 0.004)













Mean SD Mean SD Mean SD Mean SD
Cadence (steps/min) 114.49 9.65 116.94 7.67 0.446 101.37 8.07 104 11.1 0.446
Double Support (%) 21.88 2.88 20.41 3.76 0.151 27.18 5.67 27.39 5.04 0.922
Elevation at Mid Swing (cm) 0.95 0.61 1.05 0.6 0.693 3.29 0.99 3.29 0.9 0.800
Gait Speed (m/s) 1.07 0.15 1.05 0.15 0.828 0.89 0.13 0.73 0.15 0.003†
Foot Strike Angle (degrees) 16.94 5.27 12.81 4.56 0.011 17.67 3.52 11.57 5.09 0.001†
Toe Off Angle (degrees) 33.8 5.3 31.49 5.05 0.140 25.4 3.73 22.4 4.67 0.027
Stride Duration (s) 1.06 0.09 1.03 0.07 0.452 1.23 0.11 1.21 0.13 0.495
Stride Length (m) 1.12 0.13 1.08 0.16 0.553 1.04 0.12 0.85 0.18 0.006
Swing (%) 38.99 1.39 39.67 1.95 0.151 37.04 1.87 36.81 2.23 0.830
Toe Out Angle (degrees) 8.66 7.5 9.31 8.51 1.000 19.63 9.53 17.02 8.8 0.495
Lumbar—Coronal ROM (degrees) 7.85 2.11 5.84 2.44 0.010 6.31 1.72 5.16 1.72 0.142
Lumbar—Sagittal ROM (degrees) 5.81 2.44 5.58 2.55 0.711 6.31 1.15 6.88 1.72 0.854
Lumbar—Transverse ROM (degrees) 9.58 3.49 9.79 4.27 0.843 16.62 2.93 16.05 4.01 0.377
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Trunk control during gait
Interestingly, the lumbar coronal range of motion was 
one of the top gait measures discriminating both the MS 
and PD groups from their age-matched controls in the 
laboratory, but not in daily life. The inability of lumbar 
motion to discriminate during daily life might be due to 
lumbar sensor measures being affected by the exact loca-
tion of the sensor. In the laboratory, the researchers make 
sure the lumbar sensor location is consistent and stays 
securely attached throughout the testing, for all subjects, 
but it is hard to maintain a consistent sensor location 
placed by the subject in daily life conditions, and thus 
might not a reliable measure during daily life. Reduced 
lumbar range of motion while walking may reflect axial 
rigidity and loss of arm swing in the PD group [55], and 
may reflect the compensatory strategy to truncal ataxia in 
the MS group. In contrast to the reduced lumbar range of 
motion in the MS group here, our previous study found 
an excessive lumbar motion in people with very early MS 
who had normal gait speed [52].
Bout length
Longer bout lengths, such as in 1-min laboratory tests, 
are known to result in faster gait speed and other accom-
panying measures [5, 14]. There are various ways to meas-
ure the bout length. Researchers have used bout duration 
[5, 14, 31], and the distance traveled during a particu-
lar walk test [32] as bout length measures. We chose to 
define bout length in terms of a number of strides in the 
bout because it helps to eliminate the effect of gait speed, 
per se, on the bout length. Most gait bouts during daily 
life have < 15 strides in all 4 groups so the 7 m × 2 in the 
ISAW test reflected the most common bout lengths peo-
ple actually take during daily life.
Clinical implication
Our results suggest that clinicians should consider quan-
titative daily life gait behavior as an integral part of a 
functional clinical assessment. Furthermore, this study 
provides encouraging results to support the use of instru-
mented socks for daily life gait evaluation in people with 
PD and MS, and also a potential to use in clinical trials, 
with a possibility that fewer subjects will be required 
for clinical trials using this quantitative measurement of 
mobility in daily life.
Limitations
There are several limitations of the current study. First, 
we had a modest sample size of only 15–16 subjects in 
each group. This also resulted in a modest statistical 
power for detecting differences. If a larger number of 
subjects had been included, additional measures would 
Fig. 4 Wilcoxon paired test comparing laboratory versus daily life 
gait characteristics for each group (MS, MS‑Ctl, PD, and PD‑Ctl)
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have been able to discriminate between the neurologi-
cal groups from their matched controls. Further analysis 
is needed with larger cohorts to test the generalizability 
of the findings. Second, we used a conservative correc-
tion for multiple hypothesis tests. Many of the tests we 
performed were on measures of gait that at correlated 
and not statistically independent. The Bonferroni correc-
tion assumes these tests are independent, so the correc-
tion may have reduced the power of the statistical tests 
so that additional measures are actually statistically sig-
nificant. Thirdly, for daily life data, we assumed that sub-
jects attempt to be in the ON-medication state most of 
the time, and hence, we compared with laboratory walk-
ing test only with subjects with their ON state. Further, 
future studies need to determine the test–retest reliabil-
ity and sensitivity of the top mobility measures to a treat-
ment and disease progression in daily life to be useful as 
digital biomarkers for clinical trials. Finally, with larger 
cohorts, we can investigate if the paired ROCs in a labo-
ratory and daily life are statistically significant.
Conclusions
Subjects, especially people with PD, generally showed 
better gait characteristics when observed in the labora-
tory compared to over a week of daily life. Different types 
of gait characteristics discriminated PD gait or MS gait 
from their age-matched controls in the laboratory ver-
sus daily life. PD and MS gait differed from each other, 
so clinical trials need to identify the specific gait impair-
ments most sensitive for each neurological disease.
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